Research
Peyronie's
Disease
Advances in stem cell therapy for the treatment of Peyronie's disease
​
​
Regenerative medicine stands as a pioneering approach in the treatment landscape of Peyronie’s disease, leveraging the power of mesenchymal stem cell therapy. This novel treatment carries both curative and preventive potential. While human studies to date have been somewhat limited due to smaller sample sizes and brief follow-up periods, the findings are undoubtedly promising. In this comprehensive review, we encapsulate the existing literature on this transformative topic in regenerative medicine and urological care.
​
Single Intrasphincteric Injection Of Autologous Adipose-derived Stem Cells To Treat Stress Urinary Incontinence After Radical Prostatectomy: A Pilot Study
​
Our comprehensive clinical study reveals the promising role of intrasphincteric adipose-derived stem cells in progressively improving stress urinary incontinence. Over an 18-month follow-up period, significant improvements were observed as evidenced by a decrease in the 24-hour pad weight test. Moreover, enhancements in the quality of life were reported, evaluated using a validated quality of life questionnaire. This research underscores the potential of regenerative medicine in enhancing urological care.
​
Stress Urinary Incontinence
Erectile Dysfunction
Pilot I
The effect of a single intra-cavernous injection of autologous adipose-derived stem cells in patients with erectile dysfunction following radical cystectomy
​
​
A single intra-cavernosal injection of autologous adipose-derived stem cells (ADSCs) demonstrated a significant positive impact on the treatment of erectile dysfunction (ED) following radical cystectomy. The treatment showcased a robust safety profile. As early as one month post-therapy, all patients treated with ADSCs experienced a marked increase in their IEF-5 score. Further, at both 3 and 6 month intervals post-treatment, the severity of ED was reported as mild in all patients, underlining the potential of this innovative approach in urological care.
Erectile Dysfunction
Pilot II
Single intracavernous injection of autologous adipose-derived stem cells versus a single high dose of platelet rich plasma to improve erectile dysfunction: a comparative study
​
​
Our study, conducted between January 2020 and August 2022, explored the efficacy of using a one-time intracavernosal injection of Platelet-rich plasma (PRP) or adipose stem cells (ADSC) to treat severe ED unresponsive to traditional medical therapies. Results showed that both PRP and ADSC treatments improved ED, especially evident in the ADSC group, with minimal side effects.
Single Intradetrusor Injection Of Autologous Adipose-derived Stem Cells In Parkinson's Disease Patients With Overactive Bladder: A Pilot Study
​
​
In a pioneering finding within the literature, our study illustrates that intradetrusor Adipose-derived Stem Cells (ADSCs) could successfully manage overactive bladder symptoms in patients diagnosed with Parkinson’s disease. Participants who received a single intradetrusor ADSCs injection exhibited marked improvements in all bladder diary measures and a substantial reduction in OABSS. Further, patient satisfaction with the treatment, as assessed by the mean of OAB-q SF total HRQL score, improved significantly, while symptom bothers markedly decreased, highlighting the potential of this regenerative approach in managing urological symptoms associated with Parkinson’s disease.
Overactive Bladder
Ongoing projects
An update on the use of stem cell therapy for erectile dysfunction
